Cytokinetics Inc.
Description Cytokinetics, Incorporated, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. The companys drug candidates in clinical development include Tirasemtiv, a skeletal muscle troponin activator, which is in Phase II clinical trials; and CK-2127107, a pre-clinical skeletal sarcomere activator for treating diseases or medical conditions associated with skeletal muscle weakness or wasting. It is also involved in developing omecamtiv mecarbil, a cardiac muscle myosin activator for the treatment of heart failure that is in Phase I and IIb clinical trials; and conducting earlier-stage research directed to other compounds to modulate muscle contractility and other muscle functions, such as growth, energetics, and metabolism. The company has a strategic alliance with Amgen Inc. to discover, develop, and commercialize small molecule therapeutics that activate cardiac muscle contractility for applications in the treatment of heart failure. Cytokinetics, Incorporated was founded in 1997 and is headquartered in South San Francisco, California. To view the detailed information, you need to SUBSCRIBE with us. |
 |